Every FDA-ApprovedGLP-1 Medication
A factual overview of all GLP-1 receptor agonists currently available by prescription. This page provides published information about each medication — not recommendations. Always consult your prescribing healthcare provider for personalized guidance.
About This Reference
This page provides a factual reference of FDA-approved GLP-1 receptor agonist medications based on publicly available information. It includes brand names, generic names, manufacturers, FDA approval dates, approved indications, and administration methods.
This page does not include dosage information or treatment recommendations. Medication selection, dosing, and treatment plans should be determined by your healthcare provider based on your individual health profile. For a deeper look at the science behind these medications, see our What Are GLP-1 Medications? guide.
SemaglutideMedications
Semaglutide is a GLP-1 receptor agonist developed by Novo Nordisk. It is available under multiple brand names for different approved indications.
Ozempic
FDA 2017Wegovy
FDA 2021Rybelsus
FDA 2019TirzepatideMedications
Tirzepatide is a dual GIP/GLP-1 receptor agonist developed by Eli Lilly. It targets both the GLP-1 and GIP (Glucose-dependent Insulinotropic Polypeptide) receptors, distinguishing it from pure GLP-1 receptor agonists.
Mounjaro
FDA 2022Zepbound
FDA 2023AdditionalGLP-1 Medications
Several other GLP-1 receptor agonists are available and continue to be widely prescribed.
Saxenda
Victoza
Trulicity
Note: Additional GLP-1 receptor agonists exist, including exenatide (Byetta, Bydureon) and lixisenatide (Adlyxin). This page focuses on the most commonly prescribed medications. Approved indications and formulations may change — consult your prescriber for the most current information.
Clinical Trial ResultsComparison
Published average weight loss results from pivotal clinical trials. Individual results vary significantly.
| Medication | Trial | Participants | Duration | Avg. Weight Loss | Placebo |
|---|---|---|---|---|---|
Semaglutide 2.4mg Wegovy | STEP 1 | 1,961 | 68 weeks | ~14.9% | 2.4% |
Tirzepatide 15mg Zepbound | SURMOUNT-1 | 2,539 | 72 weeks | ~20.9% | 3.1% |
Liraglutide 3.0mg Saxenda | SCALE | 3,731 | 56 weeks | ~8.0% | 2.6% |
Sources: STEP 1 — Wilding et al., NEJM (2021); SURMOUNT-1 — Jastreboff et al., NEJM (2022); SCALE — Pi-Sunyer et al., NEJM (2015).
Note: Weight loss percentages represent averages from the highest dose groups in each trial. All trials included lifestyle intervention (diet and exercise counseling). Individual results vary significantly. These comparisons are informational and do not constitute medical recommendations.
Semaglutide vs.Tirzepatide
The two most-discussed GLP-1 medication classes differ in mechanism, available formulations, and clinical trial outcomes.
Semaglutide
- Pure GLP-1 receptor agonist
- Available as weekly injection and daily oral tablet
- Approved for both T2D (Ozempic) and weight management (Wegovy)
- STEP 1 trial: ~14.9% average weight loss
- Manufacturer: Novo Nordisk
Tirzepatide
- Dual GIP/GLP-1 receptor agonist
- Available as weekly injection only (currently)
- Approved for both T2D (Mounjaro) and weight management (Zepbound)
- SURMOUNT-1 trial: ~20.9% average weight loss (highest dose)
- Manufacturer: Eli Lilly
Important: Direct head-to-head comparisons between semaglutide and tirzepatide are limited. Clinical trial results should not be directly compared across different studies due to differences in study design, patient populations, and protocols. Your healthcare provider can help determine the most appropriate medication for your individual needs.
Track Any GLP-1 Medicationwith Dose AI
Regardless of which GLP-1 medication you're prescribed, Dose AI provides the same comprehensive tracking experience. Log injections, monitor nutrition, track weight trends, and record symptoms — all in one app designed specifically for GLP-1 users.
Any Medication
Ozempic, Wegovy, Mounjaro, Zepbound, Rybelsus, Saxenda, Trulicity, and more.
Injection Tracking
Log injection dates, track site rotation, and get reminders for your next dose.
AI Nutrition
Scan food with your camera for instant nutrition data. Track protein, calories, and macros.
Progress Insights
Visual weight trends, symptom patterns, and data you can share with your doctor.
Medical Disclaimer: This content is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your healthcare provider before making any decisions about your health or medications.
MedicationQuestions
Common questions about the different GLP-1 medications available.
Have More Questions?What is the difference between Ozempic and Wegovy?
Ozempic and Wegovy contain the same active ingredient — semaglutide — but are approved for different uses. Ozempic is FDA-approved for type 2 diabetes management, while Wegovy is approved for chronic weight management in adults with obesity or overweight with at least one weight-related condition. The dosing schedules also differ. Consult your healthcare provider to determine which is appropriate for you.
What is the newest GLP-1 medication?
Zepbound (tirzepatide) was the most recently approved GLP-1-related medication for weight management, receiving FDA approval in November 2023. Tirzepatide is technically a dual GIP/GLP-1 receptor agonist. Several additional medications are currently in development and undergoing clinical trials, so the landscape continues to evolve.
Are all GLP-1 medications the same?
No. GLP-1 medications differ significantly in their active ingredient, mechanism of action (pure GLP-1 vs. dual GIP/GLP-1), route of administration (injection vs. oral), approved indications, dosing frequency (daily vs. weekly), and clinical trial outcomes. For example, semaglutide and liraglutide are both GLP-1 receptor agonists but differ in dosing frequency and efficacy. Tirzepatide targets both GLP-1 and GIP receptors.
Is there a GLP-1 pill?
Yes. Rybelsus (oral semaglutide) is an FDA-approved oral GLP-1 medication taken as a daily tablet for type 2 diabetes. It must be taken on an empty stomach with no more than 4 ounces of plain water, at least 30 minutes before the first food, beverage, or other oral medication of the day. Additional oral formulations are currently in development.
Which GLP-1 medication is best for weight loss?
Clinical trials show different weight loss outcomes across GLP-1 medications. Tirzepatide (at the highest studied dose) demonstrated the greatest average weight loss at approximately 20.9% of body weight, followed by semaglutide at approximately 14.9%. However, trial results should not be directly compared across studies, and the most appropriate medication depends on your individual health profile. Your doctor can help determine the best option for you.
Does Dose AI work with all GLP-1 medications?
Yes. Dose AI is designed to track any GLP-1 medication, including Ozempic, Wegovy, Mounjaro, Zepbound, Rybelsus, Saxenda, Victoza, Trulicity, and others. The app tracks your injection schedule, nutrition, weight progress, and symptoms regardless of which specific medication you are prescribed.
Track Any GLP-1 Medicationwith Dose AI
Whether you're on Ozempic, Wegovy, Mounjaro, Zepbound, or any other GLP-1 medication — Dose AI tracks your injections, nutrition, weight, and symptoms in one place.
Free download · iOS · Premium features available
Dose AI is a tracking and information tool, not a medical device. Always consult your healthcare provider for medical advice about your GLP-1 medication.